Y-Biologics, Inc. (KOSDAQ:338840)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,600
-350 (-1.35%)
At close: Feb 27, 2026
221.61%
Market Cap 388.56B
Revenue (ttm) 3.61B
Net Income (ttm) -8.73B
Shares Out 15.18M
EPS (ttm) -668.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,082
Average Volume 199,720
Open 26,500
Previous Close 25,950
Day's Range 25,450 - 26,750
52-Week Range 5,330 - 29,100
Beta 2.58
RSI 52.37
Earnings Date n/a

About Y-Biologics

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 338840
Full Company Profile

Financial Performance

In 2024, Y-Biologics's revenue was 5.76 billion, an increase of 65.64% compared to the previous year's 3.48 billion. Losses were -6.44 billion, -69.14% less than in 2023.

Financial Statements

News

There is no news available yet.